Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars

Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars

Submitted by admin on October 25, 2017 - 10:59am
Source: 
Endpoints
News Tags: 
Sandoz
Novartis
FDA
biosimilars
Headline: 
Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars

Do Not Allow Advertisers to Use My Personal information